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Background: The use of Withania somnifera is increasing due to a number of its chemical constituents
found useful for health.
Objective: The present study was carried out to investigate the potential adverse effects (if any) of a
standardized Withania somnifera extract (WSE) in rats following acute and sub chronic administration.
Materials and methods: The toxicity study was performed in Wistar rats by oral administration. An acute
toxicity study was done at the dose of 2000 mg/kg. In the sub-acute study, Wistar rats (10/sex/group)
were administered via gavage 0 (control), 500, 1000, 2000 mg/kg body weight/day of WSE for 28 days.
Among two additional satellite groups, one group did not receive any drug while the second group
received 2000 mg/kg/day for 28 days. At the end of study, the animals sacriﬁced and their body weight,
hematology, serum chemistry, and histopathology evaluation was done.
Results: In acute toxicity studies, oral LD50 of WSE in Wistar rats was greater than 2000 mg/kg body
weight. Compared to the control group in sub-acute toxicity study, administration of extract did not
show any toxicologically signiﬁcant treatment related changes in clinical observations, ophthalmic ex-
amination, body weight gain, feed consumption, clinical pathology evaluation, and organ weight. He-
matological and serum chemistry parameters were within the normal limits. Terminal necropsy did not
reveal any treatment related gross or histopathological ﬁndings.
Conclusion: Based on this study, the no-observed-adverse-effect-level of WSE is 2000 mg/kg body
weight, the highest level tested.
© 2016 Transdisciplinary University, Bangalore and World Ayurveda Foundation. Publishing Services by
Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Withania somnifer Dunal, commonly known as Ashwagandha, is
an important medicinal plant in Ayurvedic and Unani system of
medicine. Various preparations of Withania somnifera (WS) are
available in the market. A signiﬁcant anti-oxidant effect of WS has
been seen in various rat brain areas, including striatum [1e4]. The
use of WS is increasing due to a number of chemical constituents
present in it are found useful for health [5]. Withaferin A is shown
to exert potent anti-angiogenic activity in vivo at doses that are
500-fold lower than those previously reported to exert the anti-., Borsad Tarapur Road, Near
ia.
ingorani).
ary University, Bangalore.
alore and World Ayurveda Foundat
es/by-nc-nd/4.0/).tumor activity in vivo. In conclusion, our ﬁndings identiﬁed a
novel mode of action of Withaferin A, which highlights the po-
tential use of this natural product for the cancer treatment or
prevention. The major constituents present inWS root are steroidal
alkaloids and steroidal lactones in a class of constituents called
withanolides [6]. The current study evaluated whether Ashwa-
gandha can be used safely in clinical trials for the treatment of
Alzheimer's disease, cancer, and Parkinson's disease.
2. Materials and Methods
The present study was conducted at Sardar Patel College of
Pharmacy, after the Institutional Animal Ethics Committee approval
of the protocol. The protocol approval number of the study is SPCP/
IAEC/RP-010/2012-13. The study protocol was prepared as per the
Organization for Economic Co-operation and Development (OECD)
Guidelines for testing the chemicals for repeated dose 28 day oralion. Publishing Services by Elsevier B.V. This is an open access article under the CC
Concentration and area values of standard Withaferin A and sample
Standard Withaferine A Sample
Concentration in mg/ml 42.45 5000
Percentage of purity 97.00 e
Area of Withaferin A 744,107 4,065,405
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(Original 1981, revised in 1995) and Section 408 (OECD Guideline,
1995). The study was conducted in compliance with the OECD
principle of good laboratory practices [22,23].
2.1. Test substance
TheWS root extract was supplied by Pharmanza Herbal Pvt. Ltd.,
Gujarat, India. It was a brown powder, standardized to contain no
<3% Withaferin A by high-performance liquid chromatography
(HPLC) analysis (USP method). The appropriate amount of WS
extract (WSE) was dissolved in distilled water to make a homoge-
neous solution. Solutions containing concentrations of 200, 100, 50,
and 0 mg/ml were prepared daily prior to administration. The
required solutions were administered to rats daily via oral gavage.
2.2. Preparation of extract
Authenticated WS roots were used to prepare the extract. Roots
were powdered using a grinder and then extracted with methanol.
Extract thus obtained was concentrated on rotator evaporator to
distil methanol and to obtain a thick paste. 250 g of the thick paste
of methanolic extract again extracted with 500 ml of ethyl acetate
in Soxhlet extractor for 3 h at 65 C temperature and then
concentrated on rotator evaporator. Concentrated extract ﬁnally
put in the drier to get dry powder.
2.3. High-performance liquid chromatography proﬁling of W.
somnifera extract
The samplewaspreparedbydissolving250mgofWSE (Withania
somnifera extract) in 50 ml methanol. The sample was passed
through membrane ﬁlter before injecting 20 ml in columnMinutes
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Fig. 1. Chromatogram of Wit(Phenomenex, LUNA C18 (2), 5u250X4.6). The mobile phase used in
HPLCwas the combinationof 1mMKH2PO4þ0.05%phosphoric acid
and acetonitrile. Flow rate was maintained at 1.5 ml/min and ul-
traviolet detection performed at 227 nm [Fig. 1]. Ninety-seven
percent pure Withaferin A used as a primary reference standard
[Fig. 2].
2.4. Quantiﬁcation of Withaferin AFormula to calculate percentage of Withaferin A in WSE:
Amount of active present ð%Þ ¼ Area of sample
Area of standard
 Concentration of standard
Concentration of sample
 Purity of standard
Percentage of Withaferin A in WSE is 4.5.2.5. Experimental animals
Healthy young female Wistar rats were used. Though there is
little difference in sensitivity to LD50 studies between the sexes,
female rats are known to be more sensitive than males.4 25 26 27 28 29 30
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Fig. 2. Chromatogram of Withaferin A primary reference standard.
S.B. Patel et al. / Journal of Ayurveda and Integrative Medicine 7 (2016) 30e3732Nonpregnant rats were randomly selected, marked for identiﬁca-
tion, and housed in polypropylene cages in groups of ﬁve for 5 days
prior to dosing. The ambient temperature in the experimental
laboratory was maintained at 22 C (±3 C). Using artiﬁcial lighting,
maintaining 12 h light and 12 h dark cycles were maintained.
Standard pellet diet was given with water ad libitum.
For experiment designed to determine oral LD50 ofWSE sighting
study was done on one rat which was administered 2000 mg/kg
WSE. Signs of toxicity were observed for 14 days. No toxic effects
were seen in the sighting study; hence 2000 mg/kg dose was
selected for the main study in ﬁve rats. Rats were administered the
dose of 2000 mg/kg of WSE and signs and symptoms of toxicity
were observed. On day 15, all the animals were euthanized and
gross pathological examinations were done.
For sub-acute study, young, healthy rats of both sexes were
used. They were divided into six groups each having ﬁve each of
male and female. Rats were given oral (gavage) WSE of root in
the doses of 0 (Group I control), 500 (Group II low-dose), 1000
(Group III mid dose), 2000 (Group IV high-dose) mg/kg/day for
28 days. Two additional satellite groups of animals received
0 (Group V) and 2000 (Group VI) mg/kg/day for 28 days. During
the course of sub-acute study, all animals were provided an ad
libitum feed, until the day prior to the scheduled euthanasia. The
signs and symptoms of toxicity were observed for 28 days and
body weight was measured on 0, 7, 14, 21, and 28 days. On day 28,
animals from Groups I to IV were euthanized, blood was collected
from a retro orbital vein for hematological and biochemical es-
timations. Then animals were sacriﬁced for organ weight, gross
necropsy, and histopathology. Group V and VI were observed
further for 14 days after 28 days dosing. On day 42, animals of
both groups were euthanized, blood was collected from the an-
imals for hematological and biochemical estimations, and ani-
mals were sacriﬁced for organ weight, gross necropsy, and
histopathology.2.6. Clinical observations and body weight
All animals were observed twice daily for morbidity and mor-
tality. Clinical examination included any abnormal physical and
behavioral changes. The observations included change in the skin,
fur, eyes, mucus membranes, secretions, excretion, and autonomic
activity. Changes in gait, posture and response to handling as well
as the presence of clonic or tonicmovements, stereotypes or bizarre
behavior were recorded. Body weight of all animals was measured
on day 0, 7, 14, 21, and 28.
2.7. Hematological parameters
The hematological examination was done at the end of the test
period, hemoglobin (Hb) concentration, erythrocyte count, re-
ticulocytes, total and differential leucocytes count, platelet count,
clotting time (CT), activated partial thromboplastin time (APTT),
prothrombin time, and reticulocyte counts were performed.
2.8. Serum chemistry
The standardized diagnostic kits (Q Dx by Parimal Healthcare
manufactured under license fromDiasyn Diagnostic SystemGmbH)
were used for estimating glucose, cholesterol, triglycerides, urea,
creatinine, aspertate aminotransferase (AST), alanine transaminase
(ALT), alkaline phosphate, total bilirubin, protein, albumin, glob-
ulin, sodium, phosphorus, calcium, chloride, blood urea nitrogen,
and cholinesterase estimation.
2.9. Histopathology
All rats in the study were subjected to detailed gross necropsy
which included a careful examination of external surfaces of the
body, oriﬁces and cranial, thoracic and abdominal cavity and their
S.B. Patel et al. / Journal of Ayurveda and Integrative Medicine 7 (2016) 30e37 33contents. The liver, kidneys, adrenals, testes, epididymides, pros-
tate, seminal vesicles, thymus, spleen, brain, and heart of all ani-
mals were trimmed of any adherent tissues. Their wet weight was
recorded. For histopathology examinations, tissues were processed
into parafﬁn blocks; ultrathin sections were dewaxed and were
stained with hematoxylin and eosin.
3. Results
3.1. Acute toxicity study
In acute toxicity studies, oral LD50 of WSE in Wistar rats was
>2000 mg/kg body weight. The day 14 observation in acute oral
toxicity study and weekly body weight measurement did not show
any toxic effects in rats. Therewas no abnormal behavior during the
ﬁrst 30 min (after dosing) and periodically for ﬁrst 24 h and daily
thereafter for 14 days. Administrations of WSE did not produce any
organ atrophy, hypertrophy, and degenerative or inﬁltrative lesions.
3.2. Sub-acute toxicity
All animals survived until the scheduled necropsy in both 28
days and satellite group. Physical and behavioral examination did
not reveal any treatment related adverse effects in any of the
groups receiving 500 mg/kg/day, 1000 mg/kg/day and 2000 mg/kg/
day of WSE. As compared to control group, no biological signiﬁcant
effects of WSE were noted on body weight gain. These results
suggest that administration of WSE up to 2000/mg/kg/day to rats
for 28 days has no adverse effect on the clinical observations and
body weights. Similarly in satellite group as well no adverse effects
were observed.
3.3. Feed and water consumption
Feed and water consumption in a different group of animals
receiving WSE was similar in both satellite and control groups.
These results show that administration of WSE up to 2000 mg/kg/
day for 28 days to rats did not affect water and feed consumption.
3.4. Clinical pathology
3.4.1. Hematology
There was no treatment related the adverse effect of WSE on
hematological parameters in females. However, some staticallyTable 1
Effect of Ashwagandha root extract on hematological parameters of female rats (sub-acu
Parameters Unit Control
RBC 106/cm 7.39 ± 0.39
WBC 103/cm 8.92 ± 0.33
Lymphocytes % 76.0 ± 1.04
Neutrophils % 23 ± 1.04
PCV % 47.6 ± 2.58
MCV fL 54.8 ± 1.46
MCH Pg 15.0 ± 1.13
Platelets 103/cm 901.8 ± 50.98
Hemoglobin g/dl 10.25 ± 0.4
CT min 1.34 ± 0.01
APTT s 25.2 ± 1.31
Prothrombin time s 19.2 ± 1.1
Reticulocytes % 0.68 ± 0.02
All value are expressed asmean ± SEM (n¼ 5). The data were statistically analyzed by one
to normal control. APTT: Activated partial thromboplastin time, CT: Clotting time, MCH
volume, RBC: Red blood cell, WBC: White blood cell, SEM: Standard error of mean.signiﬁcant differences were noted when control and treatment
group were compared. There was statically signiﬁcant increase of
Hb in groups treatedwith 500 and 2000mg/kg/day ofWSE inwhite
blood cell (WBC) in a group treated with 2000 mg/kg/day of WSE.
There were statically signiﬁcant decreases in reticulocyte at
1000 mg/kg/day dose level and prothrombin time at 2000 mg/kg/
day. However, values of CT and APTTof all treatment groupswere in
normal laboratory range, and these changes were considered as
incidental not treatment related. There was a statistically nonsig-
niﬁcant increase in the values of red blood cells, packed cell volume
(PCV), lymphocytes and platelets; however, the changes were
within normal laboratory range [Table 1].
There was no treatment related adverse effect of WSE observed
in hematological parameters in male rats. However, some statisti-
cally signiﬁcant differences were notedwhen the control group and
treatment group were compared. A statistically signiﬁcant increase
in Hb and mean corpuscular volume was observed in the group
treated with 2000 mg/kg/day of WSE and also in PCV in a group
treated with 500 and 2000 mg/kg/day of WSE. The change in PCV
was within normal laboratory range and considering no changes in
related endpoints, was not considered treatment related. There
were no changes in any other hematological measures [Table 2]. In
the recovery group, there were no other statistically signiﬁcant
differences when the respective control and treatment groups were
compared. There were statistically nonsigniﬁcant increases in
WBCs, mean corpuscular hemoglobin, APTT, platelets, and Hb% in
both male and female treatment group. These variations were
within the normal laboratory range. Increases in these values were
not considered as toxicologically relevant [Table 3].3.4.2. Serum chemistry
There was no treatment related biologically signiﬁcant adverse
effects of WSE on serum chemistry of female and male rats. In the
recovery group, there is a signiﬁcant decreased in mean values of
glucose, cholesterol, triglyceride in extract treated female andmale.
All these variations were marginal and within the normal labora-
tory ranges. Decreases in these values were not considered as
toxicologically relevant. Therewere no other statistically signiﬁcant
differences when the respective control and treatment groups were
compared. The results of serum chemistry analysis from the
treatment and recovery groups show that administration of WSE
doses up to 2000 mg/kg to rats for 29 days did not cause toxico-
logically signiﬁcant adverse effects [Table 4].te).
mg/kg
500 1000 2000
7.58 ± 0.29 8.21 ± 0.57 8.95 ± 0.42
9.78 ± 0.90 10.32 ± 0.87 10.54 ± 0.94*
77.6 ± 2.24 81.6 ± 2.94 77.6 ± 0.92
21.4 ± 2.24 17.4 ± 2.94 21.4 ± 0.92
48.4 ± 1.74 52.6 ± 1.5 53.2 ± 1.33
58.2 ± 0.79 50.4 ± 0.54 50.0 ± 1.80*
15.6 ± 0.92 17.4 ± 0.39 17.8 ± 0.67
905 ± 31.64 908.2 ± 29.35 918.6 ± 30.29
11.98 ± 0.43 13.14 ± 0.63* 15.18 ± 1.01*
1.32 ± 0.01 1.28 ± 0.05 1.27 ± 0.04
22.8 ± 0.79 22.6 ± 0.97 21.6 ± 1.02
15.8 ± 1.02 15.4 ± 0.66 15.2 ± 0.7*
0.79 ± 0.04 0.48 ± 0.087* 0.61 ± 0.01
-way ANOVA followed by Dunnett test. *P < 0.05, statistically signiﬁcant as compared
: mean corpuscular hemoglobin, MCV: Mean corpuscular volume, PCV: Packed cell
Table 2
Effect of Ashwagandha root extract on hematological parameters of male rats (sub-acute).
Parameters Unit Control mg/kg
500 1000 2000
RBC 106/cm 8.28 ± 0.21 8.47 ± 0.37 8.86 ± 0.52 9.04 ± 0.55
WBC 103/cm 10.27 ± 1.02 11.57 ± 0.71 12.05 ± 0.73 12.35 ± 0.68
Lymphocytes % 80.2 ± 1.35 81 ± 1.13 81.4 ± 1.5 82 ± 1.94
Neutrophils % 18.8 ± 1.35 18 ± 1.14 17.6 ± 1.5 17 ± 1.94
PCV % 47.2 ± 1.06 50.8 ± 0.85 52 ± 1.13* 52.2 ± 1.28*
MCV fL 50.6 ± 1.62 53.6 ± 0.39 54 ± 0.89 55.6 ± 0.92*
MCH Pg 15 ± 0.89 16.8 ± 0.91 17.2 ± 1.1 15.6 ± 1.1
Platelets 103/cm 894.6 ± 31.1 906.4 ± 31.74 912.4 ± 52.77 913.6 ± 48.57
Hemoglobin g/dl 10.13 ± 0.29 11.18 ± 0.31 11.50 ± 0.1 13.53 ± 1.05*
CT min 1.32 ± 0.01 1.31 ± 0.03 1.13 ± 0.09 1.15 ± 0.05
APTT s 24 ± 0.85 23.8 ± 0.15 24.2 ± 0.73 23.2 ± 0.7
Prothrombin time s 16.8 ± 1.06 16.4 ± 1.11 16.2 ± 1.46 14 ± 0.54
Reticulocytes % 0.74 ± 0.02 0.67 ± 0.02 0.65 ± 0.04 0.62 ± 0.06
All value are expressed asmean ± SEM (n¼ 5). The data were statistically analyzed by one-way ANOVA followed by Dunnett test. *P < 0.05, statistically signiﬁcant as compared
to normal control. APTT: Activated partial thromboplastin time, CT: Clotting time, MCH: Mean corpuscular hemoglobin, MCV: Mean corpuscular volume, PCV: Packed cell
volume, RBC: Red blood cell, WBC: White blood cell, SEM: Standard error of mean.
Table 3
Effect of Ashwagandha root extract on hematological parameters of female and male rats (satellite groups).
Parameters Unit Female Male
Control 2000 mg/kg Control 2000 mg/kg
RBC 106/cm 7.53 ± 0.36 7.61 ± 0.29 7.87 ± 0.57 8.11 ± 0.55
WBC 103/cm 8.14 ± 1.00 8.66 ± 1.03 9.61 ± 1.04 10.31 ± 1.27
Lymphocytes % 75.6 ± 1.8 78.4 ± 1.43 76.6 ± 0.80 78.0 ± 0.89
Neutrophils % 23.4 ± 1.8 20.6 ± 1.43 22.4 ± 0.80 21.0 ± 0.89
PCV % 41.8 ± 2.9 42.2 ± 2.58 48.2 ± 1.23 49.8 ± 1.46
MCV fL 53.2 ± 2.12 54.4 ± 1.29 59.4 ± 0.86 60.0 ± 2.44
MCH Pg 16.8 ± 0.7 18.2 ± 0.48 17.4 ± 0.67 19.4 ± 1.20
Platelets 103/cm 882.6 ± 34.7 888.6 ± 14.68 899.6 ± 35.4 903.8 ± 29.87
Hemoglobin g/dl 10.43 ± 0.36 11.48 ± 0.45 10.68 ± 0.59 10.71 ± 0.4
CT min 1.33 ± 0.01 1.31 ± 0.02 1.39 ± 0.04 1.35 ± 0.01
APTT s 24.6 ± 0.79 20.6 ± 0.50* 23.8 ± 1.65 22.2 ± 1.06
Prothrombin time s 19.4 ± 1.59 15.2 ± 1.39 19.2 ± 0.91 17.2 ± 1.23
Reticulocytes % 0.67 ± 0.29 0.70 ± 0.03 0.80 ± 0.02 0.73 ± 0.32
All value are expressed as mean ± SEM (n¼ 5). The data were statistically analyzed by one-way ANOVA. *P < 0.05, statistically signiﬁcant as compared to normal control. APTT:
Activated partial thromboplastin time, CT: Clotting time, MCH: Mean corpuscular hemoglobin, MCV: Mean corpuscular volume, PCV: Packed cell volume, RBC: Red blood cell,
WBC: White blood cell, SEM: Standard error of mean.
Table 4
Effect of Withania somnifera extract on serum chemistry parameters of female and male rats (satellite groups).
Parameters Unit Female Male
Control 2000 mg/kg Control 2000 mg/kg
Glucose mg/dl 80.4 ± 2.5 73 ± 3.73* 100.2 ± 3.02 92.8 ± 3.76*
Cholesterol mg/dl 84 ± 1.69 70.4 ± 3.04* 113 ± 3.73 92.2 ± 2.41*
Triglyceride mg/dl 58.2 ± 3.05 53.8 ± 3.62 67.6 ± 4.02 65.0 ± 3.26
Urea mg/dl 35.6 ± 1.04 32.4 ± 1.07 41.6 ± 0.80 40.6 ± 1.28
Creatinine mg/dl 0.70 ± 0.03 0.67 ± 0.008 0.81 ± 0.02 0.78 ± 0.006
AST IU/L 119 ± 2.07 120 ± 5.06 137.6 ± 4.32 139.4 ± 5.4
ALT IU/L 48.6 ± 2.39 46.2 ± 3.26 42.2 ± 2.78 40.2 ± 3.22
ALP IU/L 79 ± 4.21 75.6 ± 4.87 84.6 ± 4.19 82.2 ± 4.18
Total billirubin mg/dl 0.23 ± 0.008 0.22 ± 0.008 0.45 ± 0.01 0.43 ± 0.008
Protein g/dl 7.24 ± 0.03 7.29 ± 0.04 7.50 ± 0.12 7.74 ± 0.09
Albumin g/dl 3.95 ± 0.07 4.08 ± 0.02 4.00 ± 0.12 4.16 ± 0.08
Globulin g/dl 3.20 ± 0.09 3.23 ± 0.25 4.01 ± 0.34 4.26 ± 0.41
Sodium mEq/L 134.4 ± 1.43 132.8 ± 1.98 140.4 ± 0.50 139.2 ± 1.49
Potassium mEq/L 4.08 ± 0.23 4.18 ± 0.23 4.22 ± 0.29 4.23 ± 0.37
Phosphorus mEq/L 4.85 ± 0.15 4.72 ± 0.09 5.11 ± 0.09 4.98 ± 0.03
Calcium mg/dl 9.50 ± 0.37 9.00 ± 0.35 7.79 ± 0.10 7.51 ± 0.35
Chloride mEq/L 100.8 ± 1.01 103.6 ± 1.07 106.3 ± 3.03 107.2 ± 4.24
GGT U/L 7.382 ± 0.15 7.236 ± 0.06 7.70 ± 0.08 7.55 ± 0.15
BUN mg/dl 17.4 ± 0.62 15.43 ± 0.75 23 ± 0.70 22.4 ± 0.80
Cholinesterase U/ml 0.83 ± 0.02 0.722 ± 0.04 0.9 ± 0.05 0.804 ± 0.02
All value are expressed as mean ± SEM (n ¼ 5). The data were statistically analyzed by one-way ANOVA. *P < 0.05, statistically signiﬁcant as compared to normal control. ALP:
Alkaline phosphate, ALT: Alanine transaminase, AST: Aspartate aminotransferase, BUN: Blood urea nitrogen, GGT: Gamma glutamyl transferase, SEM: Standard error of mean.
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Fig. 3. Brain (H and E, 400): Normal brain histologic structure, no signs of cell degeneration and necrosis/cell damage.
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No treatment-related and biological signiﬁcant changes in the
value of organ weights were noted in female and male rats
following administration of WSE.
In this study, repeated dose administration of WSE to the extent
of 2000 mg/kg/day for 28 days did not produce any organ atrophy,
hypertrophy, and degenerative or inﬁltrative lesion.
3.4.4. Microscopic examination
Therewas no treatment related histopathological ﬁndings in the
acute group and satellite group. Similarly in the sub-acute group
and satellite group no treatment related microscopic changes were
observed. All ﬁndings observed were consistent with the normal
background lesions in clinical normal rats of the age and strain used
in this study. They were considered spontaneous and/or incidental
in nature and unrelated to the treatment. Results from the present
study suggest that administration of WSE at a dose of 2000 mg/kg/
day to rats for 28 days has no adverse microscopic effects
[Figs. 3e6].
4. Discussions
Root powder of WS is being used in the Ayurvedic system of
medicine since ages, and it is found to be safe. Pure alcoholic or
hydro alcoholic extracts of WS are not mentioned in Ayurveda, andFig. 4. Heart: Normal archistructure of heart, with cardiac muscle and pericardithe content of phytochemicals in such extracts is higher compared
to raw powder. Animal toxicity studies with such extracts help to
calculate safe starting doses in humans. A sub-acute toxicity study
with hydroalcoholic extract of WS showed no evidence of toxic
effect or mortality in Wistar rats [7]. Similarly, hydro alcoholic
extract of WS found to be safe in sub-acute toxicity study involving
rats and mice [8]. However the content of Withaferin A in these
hydro alcoholic extracts are not reported. Our experience with the
extraction shows that hydro alcoholic extract will have <1% of
Withaferin A. Today, there is a lot of interest in the standardized
extract of Ashwagandha for its use as an adjuvant therapy in cancer
treatment as it is found to have radiation enhancing activity.
Withaferin A and withanoloids have been tested for their anti-
cancer activity and Withaferin A has shown promises in the treat-
ment of cancer [9e11]. Ashwagandha extract is also found to have
immunomodulatory effect in animal models [14e21]. So there was
a need to conduct a studywith a higher concentration ofWithaferin
A. We chose this extract which is easy to make as well it has a full
range of withanoloids and has 4.5% of Withaferin A.
In the present study, increase in Hb and WBC count and de-
creases in reticulocyte and prothrombin time were observed
however the values of all treatment groups were in normal labo-
ratory range. Hence, the above changes were considered as inci-
dental and are not treatment related. Hb is found to be increased
in normal limits when the animals treated with WSE [12].um. No signs of degeneration and necrosis/inﬂammation or other changes.
Fig. 5. Liver (H and E, 400): Normal liver archistructure at high power, no hypostatic congestion at portal vein, no signs of tissue damage or malignancy.
Fig. 6. Kidney: Normal tubular structure and glomerular structure in treated and control group. No signs of damage to tubules.
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showed a signiﬁcant increase in AST. Compared to control group, a
signiﬁcant increase in bilirubin in the group receiving 1000 and
ALT in groups receiving 2000 mg/kg/day of WSE was observed.
The increase in activities of AST and ALT represent liver damage
but an increase of levels of AST; ALT and bilirubin were in normal
range, so they were not considered toxicologically signiﬁcant. Even
these changes did not reﬂect histopathology changes of the liver.
One sub-acute toxicity study of a combination of Ashwagandha
and Ginseng reported two pathological incidents of emphysema
and focal calciﬁcation in seminiferous tubules in rats. Such path-
ological incident may have caused due to the combination or
ginseng only because no such pathological incidents seen in the
present study where WSE used contains a higher percentage of
Withaferin A [12].
Human clinical study with water extract of Ashwagandha and
an animal toxicity study with water extract of Ashwagandha and
Ginseng reported the increase in body weight and appetite. But a
hydro alcoholic extract of WS and the extract used in the present
study did not cause any organ or body weight gain. The appetite
was also unchanged [7,12].
Though exact extrapolation of animal toxicity data to humans is
difﬁcult, some hematological ﬁndings of present study such asdecrease in the levels of triglyceride, cholesterol, and urea are also
get to see in an exploratory clinical study of Ashwagandha in
healthy human volunteers [13]. In summary, the results of sub-
acute toxicity suggest that oral administration of WSE containing
4.5% of Withaferin A at level up to 2000 mg/kg/day does not cause
adverse effects in male and female rats.5. Conclusion
Based on the study, the no-observed effect level of the extract
was found to be 2000 mg/kg/day. Still we recommend 90 days sub-
acute toxicity study as well as prenatal developmental toxicity
study of WSE containing 4.5% of withaferin for further safety
evaluation.Support of support
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